Policy · 2h ago
Montana opens door for unapproved drug sales via new review board
Montana now allows biotech companies to sell experimental drugs after minimal testing, with a $12,500 application fee to a state review board. Drugs tested on as few as 10 people can gain approval for consumer sale. The move expands the 'right to try' concept into a broader commercial pathway.
Meridian48 take
This bypasses FDA oversight, raising safety concerns while positioning Montana as a deregulation testbed for biotech—a risky experiment in itself.
Read the full reporting
Montana’s plan to become an experimental medical hub just pushed forward →
MIT Technology Review
drug-regulationright-to-try